(MCK) McKesson - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58155Q1031

MCK: Drugs, Pharmaceuticals, Medical, Supplies, Equipment, Technology

McKesson Corporation (NYSE:MCK) stands as a pivotal player in the healthcare sector, operating across multiple segments that collectively address the diverse needs of the healthcare ecosystem. Its U.S. Pharmaceutical segment distributes a broad array of pharmaceutical products, including generics, biosimilars, and over-the-counter drugs, which are crucial for cost reduction in healthcare. This segment also offers tailored solutions to oncology and specialty practices, enhancing operational efficiency and patient care outcomes.

The Prescription Technology Solutions (RxTS) segment exemplifies McKessons foray into digital health, a rapidly growing sector. By connecting patients, providers, and biopharma companies, RxTS leverages technology to improve medication adherence and streamline supply chains, positioning the company strategically in the digital transformation of healthcare.

The Medical-Surgical Solutions segment underscores the importance of logistics in healthcare, providing essential medical supplies to various healthcare settings. This segments focus on efficient distribution supports the operational stability of healthcare facilities, contributing significantly to McKessons diversified revenue streams.

Internationally, McKesson extends its reach into global markets, navigating the complexities of varied regulatory landscapes while addressing the growing demand for healthcare products. This segment highlights the companys ability to adapt and thrive in diverse environments, offering a balanced growth opportunity.

Financially, McKesson presents a compelling case for investors. A high P/E ratio suggests market confidence in its growth potential, while a lower P/S ratio may indicate undervaluation relative to its revenue, offering a strategic entry point for investors. The companys historical performance and scalable business model further enhance its appeal.

With a rich history dating back to 1833, McKessons reputation as a reliable intermediary in the healthcare supply chain is well-established. Its ability to maintain margins while scaling operations positions it favorably in the industry, making it a noteworthy consideration for investors seeking exposure to healthcare infrastructure and digital innovation.

Additional Sources for MCK Stock

MCK Stock Overview

Market Cap in USD 80,671m
Sector Healthcare
Industry Medical Distribution
GiC Sub-Industry Health Care Distributors
IPO / Inception 1994-11-15

MCK Stock Ratings

Growth 5y 89.4%
Fundamental 47.4%
Dividend 58.7%
Rel. Strength Industry 22.4
Analysts 4.35/5
Fair Price Momentum 797.08 USD
Fair Price DCF 373.81 USD

MCK Dividends

Dividend Yield 12m 0.33%
Yield on Cost 5y 1.74%
Annual Growth 5y 9.89%
Payout Consistency 94.5%

MCK Growth Ratios

Growth Correlation 3m 93.2%
Growth Correlation 12m 46.8%
Growth Correlation 5y 98.9%
CAGR 5y 40.81%
CAGR/Max DD 5y 1.71
Sharpe Ratio 12m 1.17
Alpha 14.25
Beta 0.77
Volatility 22.71%
Current Volume 767.3k
Average Volume 20d 824.7k
What is the price of MCK stocks?
As of March 15, 2025, the stock is trading at USD 650.43 with a total of 767,267 shares traded.
Over the past week, the price has changed by +0.96%, over one month by +9.68%, over three months by +14.22% and over the past year by +23.44%.
Is McKesson a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, McKesson (NYSE:MCK) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 47.43 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MCK as of March 2025 is 797.08. This means that MCK is currently undervalued and has a potential upside of +22.55% (Margin of Safety).
Is MCK a buy, sell or hold?
McKesson has received a consensus analysts rating of 4.35. Therefor, it is recommend to buy MCK.
  • Strong Buy: 10
  • Buy: 3
  • Hold: 4
  • Sell: 0
  • Strong Sell: 0
What are the forecast for MCK stock price target?
According to ValueRays Forecast Model, MCK McKesson will be worth about 876.8 in March 2026. The stock is currently trading at 650.43. This means that the stock has a potential upside of +34.8%.
Issuer Forecast Upside
Wallstreet Target Price 666.7 2.5%
Analysts Target Price 650.5 0%
ValueRay Target Price 876.8 34.8%